Research programme: GPCR peptide ligands - Compugen

Drug Profile

Research programme: GPCR peptide ligands - Compugen

Alternative Names: CGEN-25009; CGEN-25010; CGEN-25011; CGEN-857

Latest Information Update: 02 Dec 2011

Price : $50

At a glance

  • Originator Compugen
  • Developer Compugen; University of Pittsburgh
  • Class Peptides
  • Mechanism of Action FPR2 protein stimulants; G protein-coupled receptor agonists; RXFP1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cardiovascular disorders; Pulmonary fibrosis

Highest Development Phases

  • Preclinical Cardiovascular disorders; Inflammation; Myocardial infarction; Pulmonary fibrosis

Most Recent Events

  • 30 Nov 2011 Compugen establishes collaboration with DiscoveRx Corporation for the development of GPCR peptide ligands
  • 12 Oct 2011 Pulmonary Fibrosis Foundation funds further preclincial development of CGEN 25009 in Pulmonary fibrosis in USA
  • 12 Oct 2011 Preclinical trials in Pulmonary fibrosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top